Skip to main content
NMTC
NASDAQ Industrial Applications And Services

NeuroOne to Restate Q1 Financials Due to Revenue Recognition Errors, Citing Internal Control Failures

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.72
Mkt Cap
$31.807M
52W Low
$3.274
52W High
$6.96
52W Position info
14% above low
Off High info
47% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

NMTC is trading near its 52-week low of $3.274 (14% above the low).

Summary

NeuroOne Medical Technologies will restate its Q1 2026 financial results due to accounting errors that overstated revenue by $0.5 million and understated net loss by $0.3 million, stemming from internal control failures.


Key Events · Legal and Risk Events · NMTC

  • Financial Restatement Announced

    The Audit Committee determined that the Q1 2026 financial statements (filed May 12, 2026) should no longer be relied upon and will be restated.

  • Significant Accounting Errors

    Revenue was overstated by an estimated $529,000 (22% of reported revenue), and net loss was understated by $296,000, due to errors in revenue recognition.

  • Internal Control Weaknesses

    The errors were partly due to inadequate design and implementation of internal controls and procedures for evaluating customer modified purchase orders.

  • No Intentional Misconduct

    The company stated the matters did not involve any intentional misconduct by management or employees.


Analysis · NMTC · Industrial Applications And Services

NeuroOne Medical Technologies announced it will restate its Q1 2026 financial statements, including a significant overstatement of revenue by approximately $529,000 (22% of reported revenue) and an understatement of net loss by $296,000. This is attributed to accounting errors and inadequate internal controls related to customer purchase orders. While the company states the restatement does not affect its cash position or future revenue guidance, the disclosure of unreliable financials and control weaknesses is a serious concern, especially for a company that recently issued a going concern warning.

At the time of this filing, NMTC was trading at $3.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $31.8M. The 52-week trading range was $3.27 to $6.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NMTC - Latest Insights

NMTC
Jun 12, 2026, 4:45 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.24
Real-time Price: $1.92 info
Change: -$1.32 (-41%) info
Market Cap: $16.797M info
NMTC
Jun 12, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $1.92 info
Change: -$1.32 (-41%) info
Market Cap: $16.797M info
NMTC
Jun 12, 2026, 4:32 PM EDT
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $1.92 info
Change: -$1.32 (-41%) info
Market Cap: $16.797M info
NMTC
May 12, 2026, 8:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $1.92 info
Change: -$2.18 (-53%) info
Market Cap: $16.797M info
NMTC
May 12, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.33
Real-time Price: $1.92 info
Change: -$2.41 (-56%) info
Market Cap: $16.797M info